Goldman Sachs
RVMD icon

Goldman Sachs’s Revolution Medicines RVMD Stock Holding History

Goldman Sachs’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213M Sell
2,185,500
-306,083
-12% -$30.9M 0.02% 659
2025
Q4 		$198M Buy
2,491,583
+1,753,557
+238% +$115M 0.02% 641
2025
Q3 		$34.5M Sell
738,026
-1,415,371
-66% -$55.4M ﹤0.01% 1741
2025
Q2 		$79.2M Sell
2,153,397
-11,104
-0.5% -$427K 0.01% 1040
2025
Q1 		$76.5M Sell
2,164,501
-465,651
-18% -$18.9M 0.01% 935
2024
Q4 		$115M Buy
2,630,152
+275,550
+12% +$13.9M 0.02% 735
2024
Q3 		$107M Buy
2,354,602
+906,507
+63% +$39.5M 0.02% 761
2024
Q2 		$56.2M Buy
1,448,095
+324,645
+29% +$12.1M 0.01% 1085
2024
Q1 		$36.2M Buy
1,123,450
+70,193
+7% +$2.08M 0.01% 1384
2023
Q4 		$30.2M Buy
1,053,257
+425,812
+68% +$10.2M 0.01% 1553
2023
Q3 		$17.4M Sell
627,445
-70,234
-10% -$2.08M ﹤0.01% 1932
2023
Q2 		$18.7M Sell
697,679
-438,379
-39% -$10.8M ﹤0.01% 1912
2023
Q1 		$24.6M Buy
1,136,058
+134,841
+13% +$3.32M 0.01% 1620
2022
Q4 		$23.8M Sell
1,001,217
-39,209
-4% -$834K 0.01% 1785
2022
Q3 		$20.5M Buy
1,040,426
+150,929
+17% +$3.32M 0.01% 1842
2022
Q2 		$17.3M Buy
889,497
+19,990
+2% +$389K ﹤0.01% 2022
2022
Q1 		$22.2M Buy
869,507
+175,304
+25% +$3.82M ﹤0.01% 1966
2021
Q4 		$17.5M Sell
694,203
-279,695
-29% -$7.88M ﹤0.01% 2243
2021
Q3 		$26.8M Buy
973,898
+269,641
+38% +$7.85M 0.01% 1785
2021
Q2 		$22.4M Sell
704,257
-2,434
-0.3% -$85K 0.01% 1952
2021
Q1 		$32.4M Buy
706,691
+199,625
+39% +$8.95M 0.01% 1520
2020
Q4 		$20.1M Buy
507,066
+453,272
+843% +$17.9M 0.01% 1854
2020
Q3 		$1.87M Sell
53,794
-75,056
-58% -$2.08M ﹤0.01% 3621
2020
Q2 		$4.07M Buy
128,850
+63,162
+96% +$1.99M ﹤0.01% 2949
2020
Q1 		$1.44M Buy
+65,688
New +$1.82M ﹤0.01% 3513

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs's RVMD Position: Q1 2026 in Review

Goldman Sachs reduced its Revolution Medicines (RVMD) stake by 12% in Q1 2026, selling an estimated $30.9M and leaving 2,185,500 shares worth $213M. The position accounts for 0.02% of the portfolio, ranked #659.

Goldman Sachs first reported a position in RVMD in Q1 2020 and has held it in 25 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Goldman Sachs held 2,185,500 shares of Revolution Medicines worth $213M as of Q1 2026.
  • Goldman Sachs sold 306,083 Revolution Medicines shares in Q1 2026, an estimated $30.9M.
  • Revolution Medicines made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #659 holding.
  • Goldman Sachs first reported a position in Revolution Medicines in Q1 2020 and has held it in 25 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.